Scholarlink

<p>The determinants of tumor mutation burden (TMB) in microsatellite-stable (MSS) colorectal cancer (CRC) remain unclear. This study examined the impact of clinical, environmental, and genomic factors on TMB in advanced CRC using comprehensive genomic profiling (CGP). Eighty-eight patients with advanced or recurrent CRC who underwent CGP were analyzed and compared with 701 MSS CRC cases from a public dataset. Associations between TMB and clinicopathological, environmental, and genomic factors were evaluated. The number of prior chemotherapy regimens was significantly associated with higher TMB. No associations were observed between TMB and alcohol use, smoking history, or specific chemotherapeutic classes. Although variants in <i>POLE</i> or <i>POLD1</i> were detected, all were non-pathogenic and were not linked to elevated TMB. The top 3 three most frequent genes were consistent with those in the public dataset, although variant frequencies were higher in this cohort. In MSS TMB high CRC, elevated TMB may reflect cumulative treatment-related effects rather than intrinsic hypermutagenic mechanisms, highlighting the need to interpret TMB in the context of therapeutic history.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of chemotherapy exposure on tumor mutation burden in advanced colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Tomoya Sudo,
  • Sachiko Nagasu,
  • Toshimitsu Tanaka,
  • Kenji Fujiyoshi,
  • Yusuke Kawamoto,
  • Satoshi Shimamura,
  • Junya Fukuda,
  • Maako Kikuchi,
  • Hirona Shigyo,
  • Kenichi Koushi,
  • Takahiro Shigaki,
  • Naohiro Yoshida,
  • Takefumi Yoshida,
  • Keisuke Miwa,
  • Hironori Koga,
  • Fumihiko Fujita

摘要

The determinants of tumor mutation burden (TMB) in microsatellite-stable (MSS) colorectal cancer (CRC) remain unclear. This study examined the impact of clinical, environmental, and genomic factors on TMB in advanced CRC using comprehensive genomic profiling (CGP). Eighty-eight patients with advanced or recurrent CRC who underwent CGP were analyzed and compared with 701 MSS CRC cases from a public dataset. Associations between TMB and clinicopathological, environmental, and genomic factors were evaluated. The number of prior chemotherapy regimens was significantly associated with higher TMB. No associations were observed between TMB and alcohol use, smoking history, or specific chemotherapeutic classes. Although variants in POLE or POLD1 were detected, all were non-pathogenic and were not linked to elevated TMB. The top 3 three most frequent genes were consistent with those in the public dataset, although variant frequencies were higher in this cohort. In MSS TMB high CRC, elevated TMB may reflect cumulative treatment-related effects rather than intrinsic hypermutagenic mechanisms, highlighting the need to interpret TMB in the context of therapeutic history.